UNSPSC 51312608: Antazoline mesilate or mesylate

This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H19N3.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KU470J7TY6. European Medicines Agency schedules antazoline mesilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00540MIG. The term antazoline mesilate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule antazoline mesylate under HS 29332990.

As of Q4 2014, ANTAZOLINE MESYLATE remains US FDA's Preferred Term for this commodity. Antazoline mesylate bears US NLM identifiers UMLS ID C0771474 and NCI Concept Code C95311. SMILES: CS(=O)(=O)O.C1CCC(CC1)CN(CC2=NCCN2)C3CCCCC3.

UNSPSC 51312608 Antazoline mesilate or mesylate is a Commodity code that represents a narrow pharmaceutical ingredient with minimal recent activity in state and local procurement. The source opportunities show no recent solicitations specifically for antazoline mesilate or mesylate; instead, the tagged opportunities cover broader pharmaceutical procurement categories including naloxone systems, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and OTC products. The code does not align with the work actually being solicited in these records, indicating that state and local governments are not currently purchasing antazoline mesilate or mesylate through active competitive processes.

The recent opportunities posted under this code suggest a disconnect between the code's nominal scope and actual procurement activity. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 to procure naloxone and drug deactivation systems rather than antazoline-based products. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to explore direct-to-manufacturer prescription programs broadly. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and OTC products through established wholesaler channels, with proposals due March 26, 2026. These opportunities reflect state and local demand for pharmaceutical supply chain solutions, naloxone, and generic medications, but none target antazoline mesilate or mesylate specifically. Firms evaluating this code should verify whether current procurement needs align with this particular ingredient or whether broader pharmaceutical family codes better match their product or service portfolio.